A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01) A61K 39/395 (2006.01) A61K 48/00 (2006.01) A61P 25/00 (2006.01) A61P 25/08 (2006.01) A61P 25/16 (2006.01) A61P 25/24 (2006.01) A61P 25/28 (2006.01) C07K 14/705 (2006.01) C07K 16/28 (2006.01)
Patent
CA 2361124
A method of treating or preventing development of a neurological disorder has been developed wherein a subject with the disorder, or at risk of developing a disorder, is vaccinated against a brain protein or antigen. Alternatively, the antibodies can be directly administered to the individual in need of treatment thereof. Animal studies demonstrate potent efficacy in the treatment of epilepsy, stroke and cognition in animal models vaccinated against the NMDA receptor.
On a développé une technique permettant de prévenir ou de traiter le développement ou le risque de développement d'un trouble neurologique chez un sujet, par vaccination dudit sujet contre une protéine cérébrale faisant fonction d'antigène. Selon un autre mode de réalisation, les anticorps sont directement administrés à un individu ayant besoin dudit traitement. Des études effectuées sur des animaux ont montré l'efficacité du traitement contre l'épilepsie, l'apoplexie et la cognition dans des modèles d'animaux vaccinés contre le récepteur du N-méthyle-D-aspartate (NMDA).
Auckland Technology Enabling Corporation Limited
During Matthew John
Riches Mckenzie & Herbert Llp
LandOfFree
Vaccine-mediated treatment of neurological disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine-mediated treatment of neurological disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine-mediated treatment of neurological disorders will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2021289